Why the study?
Since the 2008 World Symposium on Pulmonary Hypertension, emerging clinical data, technological advances, and expanded experience with surgical, medical, and percutaneous therapies necessitated an updated overview of diagnostic and treatment developments in chronic thromboembolic pulmonary hypertension (CTEPH).
This report provides an expert task force overview of updated diagnostic guidance and treatment options—including pulmonary endarterectomy, medical therapy, and percutaneous pulmonary angioplasty—for chronic thromboembolic pulmonary hypertension presented at the 2013 World Symposium on Pulmonary Hypertension.
Updated CTEPH diagnostic guidance may improve recognition; leaves open optimal treatment standardization across regions.
Since the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed numerous and exciting developments in chronic thromboembolic pulmonary hypertension (CTEPH). Emerging clinical data and advances in technology have led to reinforcing and updated guidance on diagnostic approaches to pulmonary hypertension, guidelines that we hope will lead to better recognition and more timely diagnosis of CTEPH. We have new data on treatment practices across international boundaries as well as long-term outcomes for CTEPH patients treated with or without pulmonary endarterectomy. Furthermore, we have expanded data on alternative treatment options for select CTEPH patients, including data from multiple clinical trials of medical therapy, including 1 recent pivotal trial, and compelling case series of percutaneous pulmonary angioplasty. Lastly, we have garnered more experience, and on a larger international scale, with pulmonary endarterectomy, which is the treatment of choice for operable CTEPH. This report overviews and highlights these important interval developments as deliberated among our task force of CTEPH experts and presented at the 2013 World Symposium on Pulmonary Hypertension in Nice, France.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2013) conducted a review in Chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary endarterectomy, medical therapy, and percutaneous pulmonary angioplasty was evaluated. Pulmonary endarterectomy remains the treatment of choice for operable CTEPH, with expanded clinical trial data supporting medical therapy and percutaneous pulmonary angioplasty.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: